ClinicalTrials.gg
CompletedNCT01093911Updated Jan 4, 2013

Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

A Phase 1 interventional study of CDP7657 and Placebo in Immune System Diseases, Autoimmune Diseases and Lupus Erythematosus, Systemic, sponsored by UCB Pharma. Completed at 8 sites in 3 countries. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-04.

Primary conditionLupus Erythematosus, SystemicRegistry: Immune System DiseasesReclassifiedWhy we changed it
Registry
Immune System Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lupus Erythematosus, Systemic
Why
  1. The study's listed conditions name Lupus Erythematosus, Systemic, a narrower term within Immune System Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Lupus Erythematosus, Systemic by UCB S.A. — 4 open to participants now, 4 under way, 2 of them phase 3. Lupus Erythematosus, Systemic · UCB S.A..

Enrollment
13th of 21
44 · median 54
Started
2010
with 2 others
Phase 1
5 of 21
2 open now
Registered
8th of 21
by date

Among the 21 studies in Lupus Erythematosus, Systemic by UCB S.A., this one is the 13th largest by enrollment, is one of 3 that started in 2010, is one of 5 in phase 1, and was the 8th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 21 studies in Lupus Erythematosus, Systemic by UCB S.A. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Lupus Erythematosus, Systemic by UCB S.A., or all of them as a file.
02

Study summary

To evaluate safety, tolerability, pharmacokinetics and immunogenicity of CDP7657

03

Conditions studied

  • Immune System Diseases
  • Autoimmune Diseases
  • Lupus Erythematosus, Systemic
  • Skin and Connective Tissue Diseases
  • Connective Tissue Disease

Keywords

  • Lupus
  • SLE
04

In context

Lupus Erythematosus, Systemic Reclassified

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

This study's enrollment of 44 is below the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.

Browse Lupus Erythematosus, Systemic studies →

Lead sponsor

UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.

Compared within Lupus Erythematosus, Systemic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Immune System Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Volunteers and subjects with SLE

Exclusion criteria

Exclusion Criteria:

  • Severe neuropsychiatric or severe renal SLE
  • History of chronic, recurrent, or recent severe infection
  • Significant hematologic abnormalities
  • History of cancer, heart failure, renal disease, liver disease or other serious illness
06

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    CDP7657

    CDP7657 in dose escalating cohorts

    Biological: CDP7657

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • BiologicalCDP7657

    Ascending single doses of CDP7657

  • OtherPlacebo

    Placebo: 0.9% sodium chloride aqueous solution

07

What researchers measure

Primary outcomes

  1. Assessment of safety of CDP7657 as per Adverse Event (AE) reporting

    Time frame: Day 0 to 119

Secondary outcomes

  1. Maximum plasma concentration (Cmax)

    Time frame: Day 0 to 119

  2. Time corresponding to Cmax (Tmax)

    Time frame: Day 0 to 119

  3. Terminal elimination half-life (t 1/2)

    Time frame: Day 0 to 119

  4. Plasma levels of anti-CDP7657 antibodies

    Time frame: Day 0 to 119

08

Study locations

8 sites
  • 6
    Leuven, Belgium
  • 9
    Sofia, Bulgaria
  • 1
    Berlin, Germany
  • 2
    Erlangen, Germany
  • 3
    Frankfurt, Germany
  • 4
    Hannover, Germany
  • 8
    Kiel, Germany
  • 7
    Münster, Germany
09

References and documents

Publications

  • Tocoian A, Buchan P, Kirby H, Soranson J, Zamacona M, Walley R, Mitchell N, Esfandiari E, Wagner F, Oliver R. First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus. Lupus. 2015 Sep;24(10):1045-56. doi: 10.1177/0961203315574558. Epub 2015 Mar 16. PubMed 25784719 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2010
First posted
Mar 26, 2010
Start
Mar 2010
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Last update
Jan 4, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01093911
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Mar 26, 2010
Start date
Mar 2010
Primary completion
Dec 2012
Completion
Dec 2012
Last update
Jan 4, 2013

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapirolizumab pegol

Start the discussion